Mark J Rivard
Overview
Explore the profile of Mark J Rivard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
1665
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Esmaelbeigi A, Kalinowski J, Tomic N, Rivard M, Vuong T, Devic S, et al.
Med Phys
. 2024 Oct;
52(1):662-672.
PMID: 39460996
Background: Large reported variability in the material composition and geometrical components of the Xoft electronic high dose rate brachytherapy causes inter-source discrepancy in the source output. This variability is due...
2.
Fletcher E, Ballester F, Beaulieu L, Morrison H, Poher A, Rivard M, et al.
Med Phys
. 2024 Jul;
51(8):5783-5784.
PMID: 38958554
No abstract available.
3.
Chen Z, Li X, Brenner D, Hellebust T, Hoskin P, Joiner M, et al.
Med Phys
. 2024 May;
51(6):3850-3923.
PMID: 38721942
Brachytherapy utilizes a multitude of radioactive sources and treatment techniques that often exhibit widely different spatial and temporal dose delivery patterns. Biophysical models, capable of modeling the key interacting effects...
4.
Semeniuk O, Yu E, Rivard M
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473430
What treatment options are there for patients having uveal melanoma? A randomized, prospective, multi-institutional clinical trial (COMS) showed no difference in survival between brachytherapy and enucleation for medium-sized lesions. With...
5.
Hepel J, Leonard K, Yashar C, Einck J, Sha S, DiPetrillo T, et al.
Int J Radiat Oncol Biol Phys
. 2023 Dec;
119(3):878-883.
PMID: 38151190
Purpose/objective(s): NIBB has potential advantages over other APBI techniques by delivering highly conformal radiation with minimal collateral dose to the heart and lung compared with external beam techniques, but unlike...
6.
Fletcher E, Ballester F, Beaulieu L, Morrison H, Poher A, Rivard M, et al.
Med Phys
. 2023 Sep;
51(1):694-706.
PMID: 37665982
Purpose: A joint Working Group of the American Association of Physicists in Medicine (AAPM), the European Society for Radiotherapy and Oncology (ESTRO), and the Australasian Brachytherapy Group (ABG) was created...
7.
Beaulieu L, Ballester F, Granero D, Carlsson Tedgren A, Haworth A, Lowenstein J, et al.
Med Phys
. 2023 Jul;
50(8):e946-e960.
PMID: 37427750
The introduction of model-based dose calculation algorithms (MBDCAs) in brachytherapy provides an opportunity for a more accurate dose calculation and opens the possibility for novel, innovative treatment modalities. The joint...
8.
Finger P, Stewart R, Rivard M, Beers R, Kamen J, Lama S, et al.
Brachytherapy
. 2023 Mar;
22(3):416-427.
PMID: 36948988
Purpose: Herein, we study if high-dose-rate (HDR) yttrium-90 (Y) brachytherapy could be utilized by medical physicists, radiation oncologists, and ophthalmic surgeons. Methods And Materials: Yttrium-90 (Y) beta-emitting brachytherapy sources received...
9.
Beaulieu L, Rivard M
Med Phys
. 2023 Feb;
50 Suppl 1:21-26.
PMID: 36773303
While brachytherapy is the oldest form of radiation therapy, it is also a very exciting field from both physics and clinical perspectives. From the physics standpoint, brachytherapy dosimetry is largely...
10.
Perez-Calatayud J, Ballester F, Carlsson Tedgren A, DeWerd L, Papagiannis P, Rivard M, et al.
Radiother Oncol
. 2022 Sep;
176:108-117.
PMID: 36167195
The vast majority of radiotherapy departments in Europe using brachytherapy (BT) perform temporary implants of high- or pulsed-dose rate (HDR-PDR) sources with photon energies higher than 50 keV. Such techniques...